Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring

Judianne Slish, Qing Ma, Barry S. Zingman, Richard C. Reichman, Margaret A Fischl, Barbara Gripshover, Alan Forrest, Dan Brazeau, Naomi S. Boston, Linda Catanzaro, Robin DiFrancesco, Gene D. Morse

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Atazanavir (ATV) and lopinavir (LPV) are widely used HIV-1 protease inhibitors. Like with other protease inhibitors, careful monitoring of potential drug-drug and drug-disease interactions in clinical practice is necessary. The aim of this study was to assess the impact of substance use and hepatitis virus coinfection on plasma ATV and LPV trough concentrations in HIV-positive substance users and nonusers. Individuals established on ATV (300 mg and 100 mg ritonavir daily) or LPV (400 mg and 100 mg ritonavir twice daily)-containing regimens completed two clinical visits (trough and directly observed therapy) during which dosing characteristics, concomitant medication, and substance use were recorded. Trough plasma concentrations (22-26 hours for ATV and 10-14 hours for LPV) were measured using LCMSMS. The influence of substance use was evaluated by Kruskal-Wallis test. Substance use was associated with a marked decrease in trough LPV concentrations during the trough visit (median, 5.536 and 3.791 μg/mL for nonsubstance users and substance users, respectively, P = 0.029). Significantly lower LPV trough levels were also noted among patients with active hepatitis C virus coinfection evaluated as an independent variable (median, 2.253 and 5.927 μg/mL for active and inactive/no hepatitis C virus infection, respectively, P = 0.032). Substance use and hepatitis virus coinfection had limited effects on ATV trough levels. In this cohort, despite the wide interindividual variability of ATV and LPV trough concentrations, significant associations between substance use and active hepatitis C virus infection and low LPV trough concentrations were observed. Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users.

Original languageEnglish
Pages (from-to)560-565
Number of pages6
JournalTherapeutic Drug Monitoring
Volume29
Issue number5
DOIs
StatePublished - Oct 1 2007

Fingerprint

Lopinavir
Drug Monitoring
Coinfection
Hepatitis
HIV
Monitoring
Viruses
Pharmaceutical Preparations
Hepacivirus
Ritonavir
Hepatitis Viruses
Virus Diseases
Protease Inhibitors
Directly Observed Therapy
HIV Protease Inhibitors
Plasmas
Atazanavir Sulfate
Drug Interactions

Keywords

  • Antiretrovirals
  • Atazanavir
  • Lopinavir
  • TDM

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. / Slish, Judianne; Ma, Qing; Zingman, Barry S.; Reichman, Richard C.; Fischl, Margaret A; Gripshover, Barbara; Forrest, Alan; Brazeau, Dan; Boston, Naomi S.; Catanzaro, Linda; DiFrancesco, Robin; Morse, Gene D.

In: Therapeutic Drug Monitoring, Vol. 29, No. 5, 01.10.2007, p. 560-565.

Research output: Contribution to journalArticle

Slish, J, Ma, Q, Zingman, BS, Reichman, RC, Fischl, MA, Gripshover, B, Forrest, A, Brazeau, D, Boston, NS, Catanzaro, L, DiFrancesco, R & Morse, GD 2007, 'Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring', Therapeutic Drug Monitoring, vol. 29, no. 5, pp. 560-565. https://doi.org/10.1097/FTD.0b013e31806db8ae
Slish, Judianne ; Ma, Qing ; Zingman, Barry S. ; Reichman, Richard C. ; Fischl, Margaret A ; Gripshover, Barbara ; Forrest, Alan ; Brazeau, Dan ; Boston, Naomi S. ; Catanzaro, Linda ; DiFrancesco, Robin ; Morse, Gene D. / Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. In: Therapeutic Drug Monitoring. 2007 ; Vol. 29, No. 5. pp. 560-565.
@article{8db1a4a1d13b48f0aa4e59f8e7b3adf2,
title = "Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring",
abstract = "Atazanavir (ATV) and lopinavir (LPV) are widely used HIV-1 protease inhibitors. Like with other protease inhibitors, careful monitoring of potential drug-drug and drug-disease interactions in clinical practice is necessary. The aim of this study was to assess the impact of substance use and hepatitis virus coinfection on plasma ATV and LPV trough concentrations in HIV-positive substance users and nonusers. Individuals established on ATV (300 mg and 100 mg ritonavir daily) or LPV (400 mg and 100 mg ritonavir twice daily)-containing regimens completed two clinical visits (trough and directly observed therapy) during which dosing characteristics, concomitant medication, and substance use were recorded. Trough plasma concentrations (22-26 hours for ATV and 10-14 hours for LPV) were measured using LCMSMS. The influence of substance use was evaluated by Kruskal-Wallis test. Substance use was associated with a marked decrease in trough LPV concentrations during the trough visit (median, 5.536 and 3.791 μg/mL for nonsubstance users and substance users, respectively, P = 0.029). Significantly lower LPV trough levels were also noted among patients with active hepatitis C virus coinfection evaluated as an independent variable (median, 2.253 and 5.927 μg/mL for active and inactive/no hepatitis C virus infection, respectively, P = 0.032). Substance use and hepatitis virus coinfection had limited effects on ATV trough levels. In this cohort, despite the wide interindividual variability of ATV and LPV trough concentrations, significant associations between substance use and active hepatitis C virus infection and low LPV trough concentrations were observed. Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users.",
keywords = "Antiretrovirals, Atazanavir, Lopinavir, TDM",
author = "Judianne Slish and Qing Ma and Zingman, {Barry S.} and Reichman, {Richard C.} and Fischl, {Margaret A} and Barbara Gripshover and Alan Forrest and Dan Brazeau and Boston, {Naomi S.} and Linda Catanzaro and Robin DiFrancesco and Morse, {Gene D.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1097/FTD.0b013e31806db8ae",
language = "English",
volume = "29",
pages = "560--565",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring

AU - Slish, Judianne

AU - Ma, Qing

AU - Zingman, Barry S.

AU - Reichman, Richard C.

AU - Fischl, Margaret A

AU - Gripshover, Barbara

AU - Forrest, Alan

AU - Brazeau, Dan

AU - Boston, Naomi S.

AU - Catanzaro, Linda

AU - DiFrancesco, Robin

AU - Morse, Gene D.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Atazanavir (ATV) and lopinavir (LPV) are widely used HIV-1 protease inhibitors. Like with other protease inhibitors, careful monitoring of potential drug-drug and drug-disease interactions in clinical practice is necessary. The aim of this study was to assess the impact of substance use and hepatitis virus coinfection on plasma ATV and LPV trough concentrations in HIV-positive substance users and nonusers. Individuals established on ATV (300 mg and 100 mg ritonavir daily) or LPV (400 mg and 100 mg ritonavir twice daily)-containing regimens completed two clinical visits (trough and directly observed therapy) during which dosing characteristics, concomitant medication, and substance use were recorded. Trough plasma concentrations (22-26 hours for ATV and 10-14 hours for LPV) were measured using LCMSMS. The influence of substance use was evaluated by Kruskal-Wallis test. Substance use was associated with a marked decrease in trough LPV concentrations during the trough visit (median, 5.536 and 3.791 μg/mL for nonsubstance users and substance users, respectively, P = 0.029). Significantly lower LPV trough levels were also noted among patients with active hepatitis C virus coinfection evaluated as an independent variable (median, 2.253 and 5.927 μg/mL for active and inactive/no hepatitis C virus infection, respectively, P = 0.032). Substance use and hepatitis virus coinfection had limited effects on ATV trough levels. In this cohort, despite the wide interindividual variability of ATV and LPV trough concentrations, significant associations between substance use and active hepatitis C virus infection and low LPV trough concentrations were observed. Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users.

AB - Atazanavir (ATV) and lopinavir (LPV) are widely used HIV-1 protease inhibitors. Like with other protease inhibitors, careful monitoring of potential drug-drug and drug-disease interactions in clinical practice is necessary. The aim of this study was to assess the impact of substance use and hepatitis virus coinfection on plasma ATV and LPV trough concentrations in HIV-positive substance users and nonusers. Individuals established on ATV (300 mg and 100 mg ritonavir daily) or LPV (400 mg and 100 mg ritonavir twice daily)-containing regimens completed two clinical visits (trough and directly observed therapy) during which dosing characteristics, concomitant medication, and substance use were recorded. Trough plasma concentrations (22-26 hours for ATV and 10-14 hours for LPV) were measured using LCMSMS. The influence of substance use was evaluated by Kruskal-Wallis test. Substance use was associated with a marked decrease in trough LPV concentrations during the trough visit (median, 5.536 and 3.791 μg/mL for nonsubstance users and substance users, respectively, P = 0.029). Significantly lower LPV trough levels were also noted among patients with active hepatitis C virus coinfection evaluated as an independent variable (median, 2.253 and 5.927 μg/mL for active and inactive/no hepatitis C virus infection, respectively, P = 0.032). Substance use and hepatitis virus coinfection had limited effects on ATV trough levels. In this cohort, despite the wide interindividual variability of ATV and LPV trough concentrations, significant associations between substance use and active hepatitis C virus infection and low LPV trough concentrations were observed. Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users.

KW - Antiretrovirals

KW - Atazanavir

KW - Lopinavir

KW - TDM

UR - http://www.scopus.com/inward/record.url?scp=34848824099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848824099&partnerID=8YFLogxK

U2 - 10.1097/FTD.0b013e31806db8ae

DO - 10.1097/FTD.0b013e31806db8ae

M3 - Article

VL - 29

SP - 560

EP - 565

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 5

ER -